Latest Headlines
-
Funding Boosts Endometriosis Drug Discovery Efforts
7/19/2024
A key receptor is being targeted using robotic high-throughput screening at the National Drug Discovery Centre (NDDC) to fast-track new treatments for endometriosis.
-
Irish Scientists Pinpoint New Drug Target For RSV
7/18/2024
The scientists have discovered how the dangerous Respiratory Syncytial Virus (RSV) defuses our immune response and, in doing so, have pinpointed an exciting new target for drug developers.
-
Modular Assembly Of Ethylene, Arenes And Heteroarenes
7/17/2024
Chemists at the National University of Singapore (NUS) have developed a modular approach to create 1,2-arylheteroaryl ethanes, a class of compounds important for drug discovery and pharmaceutical development, using fundamental feedstock chemicals such as ethylene, arenes and heteroarenes.
-
Junshi Biosciences Announces The Acceptance Of The Supplemental New Drug Application For Toripalimab Combined With Bevacizumab For The First-Line Treatment Of Advanced Hepatocellular Carcinoma
7/17/2024
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has accepted for review the supplemental new drug application (sNDA) for toripalimab (trade name: TUOYI®, product code: JS001) combined with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
-
Sanyou Bio Collaborates On ADC Drug Development Entering Phase I Clinical Trials
7/16/2024
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963, hereinafter referred to as "Huadong Medicine").
-
Breakthrough In High-Performance Computing And Quantum Chemistry Revolutionises Drug Discovery
7/16/2024
A breakthrough in high-performance computing (HPC) and quantum chemistry, powered by the world’s fastest supercomputer and leading technology, is set to revolutionise drug discovery and unlock new ways to target a range of diseases.
-
Genomics Plc Announces New Extension And Expansion Of Drug Discovery Collaboration With Vertex
7/16/2024
Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company's collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use human genetics and machine learning to improve the discovery and development of new precision medicines.
-
NexThera Files IND Application For Phase 1/2a Clinical Trial Of NT-101 Eye Drop For Wet AMD
7/16/2024
NexThera Co., Ltd. (CEO SaeGwang Park) announced that it has submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, a non-invasive eye drop treatment for wet age-related macular degeneration (wet AMD).
-
SOTIO Enters Into Multi-Target Antibody Agreement With Biocytogen To Expand ADC Pipeline
7/16/2024
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, and Biocytogen a global biotech company focused on the discovery of novel antibody therapeutics, today announced a research collaboration and exclusive option and license agreement.
-
Eton Pharmaceuticals Announces FDA Acceptance Of New Drug Application For ET-400 (Hydrocortisone Oral Solution)
7/15/2024
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company’s New Drug Application (NDA) for ET-400, a proprietary patented formulation of hydrocortisone oral solution, has been accepted by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025.